Bipolar Disorder Indication Strategy Report 2026: GSK-3β, Cav1.2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Treatment-Resistant Depression Indication Strategy Report 2026: NMDA, AMPA and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Major Depressive Disorder Indication Strategy Report 2026: SERT, NMDA, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Cluster Headache Indication Strategy Report 2026: CGRP, PACAP, Trials and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Migraine Indication Strategy Report 2026: CGRP, PACAP, Trials and Deal Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Lennox-Gastaut Syndrome Indication Strategy Report 2026: GABA-A, SV2A and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Dravet Syndrome Indication Strategy Report 2026: Nav1.1, SCN1A, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Epilepsy Indication Strategy Report 2026: GABA-A, SV2A, Nav1.1, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Spinal Muscular Atrophy Indication Strategy Report 2026: SMN2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Frontotemporal Dementia Indication Strategy Report 2026: PGRN, Tau, TDP-43 and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Huntington's Disease Indication Strategy Report 2026: HTT-Lowering, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

ALS Indication Strategy Report 2026: SOD1, TDP-43, Trials and Deal Landscape uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.